Disitamab Vedotin (RC48-ADC) in Breast Cancer
Recruiting · NCT05851677 · Observational (researchers observe without assigning treatment) · Lead sponsor: RenJi Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed breast cancer;
- Prior or current use of Disitamab vedotin (RC48-ADC);
Exclusion criteria
- Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Where it is running
1 location listed.
- Renji Hospital, School of Medicine, Shanghai Jiaotong University - Shanghai, China